COOPERATION AGREEMENT

1. Parties

The parties ("Parties") to this Cooperation Agreement are

(1) Shire Denmark ApS (CVR-nr. 33358008), Havneholmen 29, 1561 Copenhagen V, Denmark ("Shire") and
(2) ADHD-föreningen (CVR-nr. 12771975), Pakhusgården 50, 5000 Odense C, Denmark ("Patient Organisation").

2. Background and Purpose

The purpose of this Cooperation Agreement is to run a market research study on adult Danish ADHD-patients in order to obtain a better understanding and knowledge of the issues encountered by adult ADHD-patients and to utilize this information to promote the interests of ADHD-patients (the "Study"). The Study will include both interviews with ADHD patients, performed by the Patient Organisation, and questionnaires to be completed by ADHD patients.

For the avoidance of doubt, the Parties agree that the Study shall neither constitute direct or indirect promotion of medicinal products distributed by Shire and that no direct or indirect references to such products shall be made during the conduct of the Study.

3. Shire's Role

Shire conducts the study in co-operation with the Patient Organisation and with the assistance of a third party research institute, Thams & Nyås Management AB, in Stockholm (Thams & Nyås Management AB complying with the ICC/ESOMAR Code on Market and Social Research. Thams & Nyås Management AB has carried out the same type of study in Sweden). Shire grants the Patient Organisation full access to the results obtained from the Study.

4. Patient Organisation's Role

Patient Organisation will provide the following services ("Services") to Shire pursuant to this Cooperation Agreement:

1. Patient Organisation will distribute an invitation letter for recruiting 10 adult ADHD patients to participate in a 30 min informal telephone interview.

2. Employees of the Patient Organisation will, after being briefed by Patient Organisation and Thams & Nyås Management AB, and after having received the education that Shire requires, perform the interviews. Patient Organisation will forward the responses that differ from responses received by
Thams & Nyås in a similar survey conducted in Sweden, to Thams & Nyås Management AB. Thams & Nyås will provide the Patient Organisation with information to enable Patient Organisation to determine what responses to forward. Patient Organisation undertakes to anonymize the responses prior to sending these to Thams & Nyås Management AB, hereby making sure that none of the respondents are identifiable by Thams & Nyås Management AB. Each of the Parties and Thams & Nyås Management AB shall be individually responsible for complying with any applicable regulatory requirements with respect to pharmacovigilance. In addition, the pharmacovigilance requirements set out in Appendix 2 shall apply between the Parties.

3. Patient Organisation will include a banner or newsletter about the Study on Patient Organisation's home page, Facebook site and an ad in Patient Organisation's member magazine, containing a reference to a website, where the adult ADHD-patients can enroll in the Study by completing a questionnaire.

4. Patient Organisation shall assist adult ADHD-patients wanting to enroll in the Study but not being able to do so because they do not have internet access, or are otherwise unable to complete the questionnaire, e.g. by supplying such patients with a printed version of the questionnaire or offering support.

5. Patient Organisation will distribute 1200 flyers describing the Study to the 12 local chapters of the Patient Organisation, allowing the local chapters to distribute the flyers to their members and participants at local meetings.

The Parties agree that the goal is to obtain 200 completed questionnaires.

No patient names, references or patient lists will be disclosed to Shire or Thams & Nyås Management AB.

Thams & Nyås Management AB will produce and provide all the written materials necessary for the conduct of the Study (e.g. banners, letters, printed questionnaires and ads). For the avoidance of doubt, the use of such written materials is conditional upon Shire's and Patient Organisation's prior written approval.

5. Payment

The Patient Organisation is exempted from VAT and will therefore invoice Shire excluding VAT.

As payment for the Patient Organisation's provision of Services to Shire, Patient Organisation will receive a payment of 45,400 DKK ex VAT ("Payment"). The Parties agree that the Payment does not exceed fair market value for Patient Organisation's provision of Services.

Shire will make the Payment to Patient Organisation in accordance with the provisions of Appendix 1, which is an integral part of this Cooperation Agreement.
6. **Duration**

The duration of the Agreement is 1 year from the entry into force (cf. section 10 below).

7. **Processing of personal data**

Thams & Nyås will be responsible for all processing of data concerning identifiable persons, in connection with the Study. Thams & Nyås will keep confidential and not disclose such data, except to Shire in anonymized form. Shire will not receive, have access to, gain knowledge of, store, handle, or transfer any data on identifiable persons.

8. **Independence**

This Cooperation Agreement does not constitute an incentive to recommend specific medicinal products or to otherwise influence the Patient Organisation, its employees or its members. Nothing in this Cooperation Agreement or any agreements pertaining hereto shall contain, or have as its effect, any exclusivity, direct or indirect, between Shire and Patient Organisation.

9. **Compliance and transparency**

The Parties agree that the cooperation and the Study will be conducted in accordance with all applicable laws, ordinances, regulations and notably, the LIF/ENLI Patient Organisation Code. The Patient Organisation accepts that Shire may be required to make public this Cooperation Agreement (or a summary hereof) on its website, and that Shire may be required to provide copies of this Cooperation Agreement to third parties on request within a period of 10 years from the termination of this Cooperation Agreement.

The Patient Organisation is encouraged to disclose the fact that the Patient Organisation provides paid Services to Shire, whenever the Patient Organisation communicates in public on any matter that is related to the Services or other issues related to the Shire.

Shire is not allowed to use Patient Organisation's logo without written permission from the Patient Organisation.

10. **Entry into force**

This Cooperation Agreement enters into force with effect from the date it is signed by both Parties and has been drawn up in two (2) originals, of which each party takes one.
on behalf of Patient Organisation

Name: Camilla Louise Lydiksen
Title: Direktør
Date: 19/9/2016

on behalf of Shire

Name: Peter Gillberg
Title: Head of Medical Affairs Nordics
Date: 13/09/2016
Appendix 1 to the cooperation agreement between Shire and ADHD-foreningen

Terms of Payment

In accordance with Section 5 of the Cooperation Agreement to which this payment letter is an appendix, Shire will offer Patient Organisation a Payment of DKK 45,400.00 (ex VAT) in return for Patient Organisation's provision of Services (as defined in Section 4 of the Cooperation Agreement) to Shire. The Payment, which is remuneration for Services, is to contribute to Patient Organisation's costs for performing the Services.

The Payment will be subject to the following terms:

1. The Payment is made in accordance with all relevant regulatory guidelines including, but not limited to the LIF/ENLI Donations Code and all applicable legislation (including but not limited to the data protection laws and patient confidentiality laws) and the Patient Organisation agrees to comply at all times with such guidelines and legislation.

2. The limits of the Payment shall be:

   - Payment of DKK 45,400.00 (ex VAT) which is payable to the Patient Organisation within 30 days of the date of this letter.
   - The Patient Organisation agrees to provide Shire with a written receipt in respect of the Payment and has inserted details of the separate account into which the Payment should be paid on the form attached as Annex 1.
   - The Patient Organisation will be solely responsible for any settlement of tax on the Payment.
   - Any extension to the Payment is to be discussed and agreed in advance by Shire.
   - Shire may at any time following the Payment request and the Patient Organisation shall provide a detailed account of the use of the Payment.
   - In the event that the Patient Organisation ceases to support the Study, Shire shall be notified immediately and any unallocated Payment shall be returned to Shire within thirty (30) days.

3. Shire recognises the independence of the Patient Organisation and will not seek to influence the content of editorial material it sponsors. Shire however reserves the right to review and comment on any planned publications that arise from the research activity as a direct result of the Payment for technical accuracy only. Shire commits to complete this process in ten (10) working days from the date of notification. Any publication should clearly reference that the research activity was funded by an unrestricted grant of Shire.
4. In working with the Patient Organisation, Shire does not seek to influence the Patient’s attitude towards Shire or Shire's products in any way. The Patient Organisation will not be influenced in the advice it gives to its members and audiences regarding pharmaceutical products.

5. The Patient Organisation accepts that Shire may be required to make public this Cooperation Agreement (or a summary hereof) on its website. Such information shall remain accessible for a minimum of six months following the conclusion of the Study. Furthermore, the Patient Organisation accepts that Shire may be required to provide copies of this Cooperation Agreement to third parties on request within a period of 10 years from the termination of this Cooperation Agreement. The Patient Organisation agrees to publish details of the Payment (i.e. the amount and identity of Shire as contributor) on its website no later than one month following receipt of the Payment. Such information shall remain accessible for a minimum of two years following receipt of the Payment.

6. Shire will not make public use of the Patient Organisation’s logo and or proprietary material without written permission from the Patient Organisation. If Shire wishes to use any such material, Shire will seek the permission of the Patient Organisation and will clearly define the specific purpose and the way the logo and/or proprietary material will be used.

7. Patient Organisation explicitly consents to the transfer of the information it is going to provide, including any personal information to countries other than its home country or to any jurisdiction in the world (including and without limitation, the USA, which may not afford the same level of protection as that available in Denmark.

8. In line with the regulations governing the pharmaceutical industry, the Patient Organisation is required to declare the nature and cooperation of Shire on any materials or meetings that are sponsored by Shire. This wording of the sponsorship must be prominent and accurately reflect the company’s involvement. Hospitality arrangements at meetings must be in compliance with the Applicable Code of Practice. Funding must not be used to pay for entertainment at meetings.
Annex 1- Banking details
Appendix 2 to the cooperation agreement between Shire and ADHD-foreningen

Pharmacovigilance

Pharmacovigilance

In the course of performing the services described in this cooperation agreement between Shire and Patient Organisation, Patient Organisation may become aware of an “Adverse Event” or other “Safety Information” associated with the use of a Shire product. It is required that the Patient Organisation forward this “Safety Information” to Shire. Relevant definitions, responsibilities, and contact information are provided below.

Pharmacovigilance-specific Definitions

An “Adverse Event” is defined as any untoward medical occurrence in a patient or clinical investigation subject administered the Shire Product which does not necessarily have a causal relationship with the treatment for which the Shire Product is used. An Adverse Event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the Shire Product, whether or not related to the Shire Product. A pre-existing condition that worsened in severity after administration of the Shire Product would be considered an Adverse Event.

“Safety Information” is defined as any of the following:

(i) An Adverse Event from any source;
(ii) An Adverse Event related to a quality defect;
(iii) Reports of suspected transmission of an infectious agent via the Shire Product;
(iv) An exposure during lactation, without an associated Adverse Event;
(v) An exposure during pregnancy or at time of conception (maternal or paternal), without an associated Adverse Event;
(vi) Lack of efficacy, without an associated Adverse Event;
(vii) Overdose (symptomatic or not);
(viii) Misuse (symptomatic or not);
(ix) Potential or actual medication error (symptomatic or not);
(x) Abuse, without an associated Adverse Event;
(xi) Unintended beneficial effects;
(xii) Administration via incorrect route, (symptomatic or not);
(xiii) Occupational exposure, without an associated Adverse Event;
(xiv) Off label use, without an associated Adverse Event;
(xv) Withdrawal symptoms;
(xvi) Addiction; or
(xvii) Diversion.

Pharmacovigilance-related Responsibilities

As part of Shire’s corporate and regulatory responsibilities, Shire collects Safety Information (as defined above) on its Product(s) from various sources. Unless otherwise dictated by local regulations, Shire shall be responsible for all pharmacovigilance activities regarding the Product(s).

Training

All Patient Organisation personnel shall be trained in this process of collecting Safety Information prior to the start of the project. Patient Organisation will maintain records of training and supply training records to Shire upon request.

Safety Reporting

In the course of providing services under this Agreement, if Patient Organisation becomes aware of any Safety Information associated with the use of the Product(s), Patient Organisation shall notify Shire as soon as practicable but, in any event, not later than one (1) Business Day after receiving the Safety Information and transmit all available Safety Information to Shire at GlobalPharmacovigilance@Shire.com.

All Safety Information shall be recorded as stated by the reporter using actual (as reported) verbatim terms. All Safety Information exchanged should include the following four criteria: (1) the noted Safety Information, (2) the identity of the Product, (3) an identifiable patient, and (4) an identifiable reporter. Safety Information not containing the four (4) criteria, but at a minimum containing an identifiable suspect Product and an event, shall be forwarded to Shire for signal detection purposes no later than one (1) Business Day after becoming aware of such Safety Information. All efforts shall be made by Patient Organisation to obtain the remaining criteria. On request, Shire may provide an electronic form that can be used by Patient Organisation when reporting Safety Information to Shire.

Causality

All Safety Information collected must include a causality assessment in relation to the Product(s). If the original reporter is a healthcare professional (e.g. physician, nurse, pharmacist) and, the causality assessment is not provided, follow-up attempts shall be made to obtain causality from the reporter.

Receipt Acknowledgment
To ensure all Safety Information received by Patient Organisation was forwarded to and received by Shire, Shire shall acknowledge, via e-mail confirmation, that the Safety Information was received. If Patient Organisation has not received confirmation by Shire within one (1) business day of the date Safety Information was sent to Shire, Patient Organisation shall e-mail the Safety Information to Shire again.

Reconciliation

For reconciliation purposes, Patient Organisation shall send a list of all Safety Information transmitted by Patient Organisation to Shire over the previous month. If discrepancies are noted, the Parties shall work in good faith to ensure satisfactory resolution. Patient Organisation shall transmit reconciliation reports to PVR reconciliations@Shire.com.

Source Data Verification

As part of Shire's commitment to regulators to help ensure compliance with the pharmacovigilance-related activities performed by Patient Organisation, Patient Organisation shall be required to perform sample quality checks of the source data generated from its contacts with patients or other reporters. This process is known as source data verification. Patient Organisation shall perform source data verification on 10% of patient or other reporter contacts and shall forward the source data verification report to Shire at PVR reconciliations@Shire.com on a monthly basis. On request, Shire may forward Patient Organisation a source data verification template to assist in this process.

Compliance Oversight

Patient Organisation shall be responsible for ensuring that all Safety Information is being collected, compiled and forwarded to Shire in accordance with the procedures described herein. Shire and Patient Organisation shall conduct routine oversight meetings. The frequency of these meetings is to be determined based on the specifics of the Program. At these oversight meetings, Patient Organisation shall be expected to provide current information regarding pharmacovigilance training, safety reporting, reconciliation, and source data verification compliance.

Regulatory Activities

Should Patient Organisation receive any information concerning any investigation, inquiry or other action by any Regulatory Authority concerning the Product(s), Patient Organisation shall notify Shire at Global Pharmacovigilance@Shire.com as soon as possible but, in any event, no later than one (1) Business Day after receiving notice of such investigation, inquiry or other action. Patient Organisation shall not respond to any request or enquiry from any Regulatory Authority, without Shire's prior review and written approval.
Data Privacy

Each Party is responsible for collecting, maintaining, using and disclosing data in compliance with all applicable privacy and data protection laws, rules and regulations, including but not limited to, the European Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and the free movement of such data and the Health Insurance Portability and Accountability Act (HIPAA) of 1996. Both Parties shall implement all reasonable physical, technical and administrative safeguards to protect data from loss, misuse, unauthorized access, disclosure, alteration, or destruction. Both Parties shall notify each other promptly of any unauthorized uses or disclosures of data of which they become aware.

Audit

Shire may audit Patient Organisation if Shire, in its opinion, believes that Patient Organisation has failed to comply with the terms of these PV provisions. Further, Shire may audit Patient Organisation without cause, to ensure compliance with the terms of these PV provisions. At least two (2) weeks’ notice shall be provided before the audit commencement date. An audit shall not be conducted more than twice per calendar year unless serious compliance issues have been identified in previous audits. The audit shall be limited to the provisions contained in these PV provisions as well as any supportive documentation and processes (e.g., SOPs, Safety Information collection and reporting) that support compliance with the provisions contained herein. Audits shall be conducted in line with the appropriate regulations. There shall be no fee associated with or assessed by one Party to the other Party in conjunction with any audit. Each Party shall bear its own costs associated with any audit.

Pharmacovigilance Contacts –

Shire

<table>
<thead>
<tr>
<th>Preferred method - Email:</th>
<th><a href="mailto:GlobalPharmacovigilance@Shire.com">GlobalPharmacovigilance@Shire.com</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fax:</td>
<td>+1 484-595-8155</td>
</tr>
<tr>
<td>Overnight Delivery Only:</td>
<td>Global Pharmacovigilance and Risk Management Shire</td>
</tr>
<tr>
<td></td>
<td>300 Shire Way</td>
</tr>
<tr>
<td></td>
<td>Lexington, MA 02421, USA</td>
</tr>
</tbody>
</table>

Patient Organisation

<table>
<thead>
<tr>
<th>Email:</th>
<th><a href="mailto:info@adhd.dk">info@adhd.dk</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fax:</td>
<td>N/A</td>
</tr>
</tbody>
</table>

DK/C-ANPROM/NBLU/16/0005(1)
| Overnight delivery: | ADHD-foreningen  
Pakhusgården 50  
Dk-5000 Odense C |

Both Parties shall notify the other of any Contact changes.

The Parties hereby agree that the above language formalizes the respective responsibilities with regard to safety data exchange and pharmacovigilance for the Shire Product(s) pursuant to applicable law, regulations and guidelines.
SHIRE DENMARK A/S

and

ADHD-FORENINGEN

COLLABORATION EXTENSION AGREEMENT
THIS COLLABORATION EXTENSION AGREEMENT (the "Amendment") is made on the 7th Day of May, 2018.

BETWEEN

(1) SHIRE DENMARK A/S, a company incorporated in Denmark, with address Larsbjørnsstræde 3, 1454 København K, Denmark, with corporate registration number CVR 36392290 ("Shire"); and

(2) ADHD-FORENINGEN, a patient organisation registered in Denmark, with address at Pakhusgården 50, 5000 Odense C, Denmark with registration number CVR 12771975 ("Patient Organisation").

Shire Denmark A/S and Patient Organisation are hereinafter referred to jointly as the "Parties" and individually as a "Party".

RECITALS

(A) Shire Denmark ApS (CVR3358008), now merged into Shire, and Patient Organisation entered into a collaboration agreement in 2016 (the "Agreement").

(B) Shire and Patient Organisation now wish to extend the Agreement with an additional element of collaboration as set out below (the "Extension").

AGREED TERMS

1. Definitions and Interpretation

1.1 In this Extension, including the Recitals, unless the context requires otherwise: (a) terms defined in the Agreement will have the same meaning when used in this Extension; and (b) all of the headings are for convenience, have no legal effect and should be ignored when interpreting this Extension.

1.2 Except as otherwise provided in this Extension, the Parties agrees that the terms and conditions set out in the Agreement shall apply during the Term of this Extension.

1.3 In the event of a conflict or ambiguity between the terms of the Agreement and the terms of this Extension, the terms of this Extension shall prevail.
2. Extension to the Original Collaboration Agreement

2.1 In addition to the collaboration set out in the original Agreement, and in the interest of both Parties to increase adult ADHD awareness amongst the ADHD community and for the lay public in general, and thereby contributing to improving the quality of life for many patients and families, the Parties herewith agrees to collaborate on the dissemination of results as follows:

a. The Patient Organisation undertakes to disseminate the information by the following actions; data processing/ graphic setup of materials, distribution of processed data material, creating online ads of results for media, preparation of article publication, creation of article, print of materials, banner with result for online use on SOME, short film of results at www.adhd.dk and SOME.

a. Shire undertakes to contribute financially with DKK 47 800 payable to the Patient Organisation by July 1, 2018.

3. General

3.1 Further assurances. Each Party agrees to execute, acknowledge, and deliver all such further instruments, and do all such further similar acts, as may be necessary or appropriate to carry out the purpose and intent of this Extension.

3.2 Counterparts. This Extension may be executed in counterparts, each of which shall be deemed to be an original and all of which, when taken together, shall constitute one instrument.

3.3 Binding Effect. This Extension shall be binding upon and inure to the benefit of the Parties hereto, their heirs, representatives, successors and permitted assigns.

3.4 Term. The duration of this Extension shall be 12 months from the date of the Extension, during which term the dissemination activities outlined in Section 2.1.a above will be executed.

3.5 Governing Law. This Amendment and any issues, disputes or claims arising out of or in connection with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) shall be governed by and interpreted in accordance with the laws of Denmark.

Agreed by the Parties through their authorized signatories:

Shire Denmark A/S
Signature: [Signature]
Name: Jacob Westin
Title: Director
Date: 29th May 2018

ADHD-Foreningen
Bakhusgården 50
DK-2500 Copenhagen C
Signature: [Signature]
Name: Camilla Dyreborg
Title: Director
Date: 15.6.2018

Document Number
C-ANPROM/DK/0142